The Comprehensive Cancer Center of Wake Forest University (CCCWFU) serves a large region in western North Carolina and contiguous regions in six adjoining states. In the last grant period, overall peer-reviewed cancer funding increased from $26 to $31 million (direct) and NCI funding increased from $12.2 to $17.7 million. Our NCI funding has increased 3.5 fold since 2000. Notable achievements include: Interdisciplinary and transdisciplinary interactions: Interprogrammatic and intraprogrammatic publications comprise 22% and 37% of publications in the Cellular Damage and Defense Program (CDD), 24% and 21% of those in the Cell Growth and Survival Program (COS), 22% and 40% in the Cancer Prevention and Control Program (CPC), and 22% and 22% of publications in the Clinical Research Program (CRP). Further, in 67%) of the peer-reviewed research grants in Summary II, CCCWFU principal investigators collaborate with other Cancer Center members as co-investigators or consultants These collaborative efforts are at highest levels since our Cancer Center began collecting these metrics. Innovative translational investigations: From our own preclinical science, we developed a portfolio of therapeutic and imaging clinical investigations. We also initiated nationally prominent programs in prostate cancer genetics, and, using our NCI-funded CCOP research base, led large-scale clinical trials in symptom management. Quality scientific contributions: Whether measured by high impact publications, NCI funding, or indisputably important contributions to cancer science and cancer care, CCCWFU investigators made important contributions to the national cancer effort. Support is requested for Cancer Center Support Grant for Years 37 through 41. The Center has four Programs: Cell Growth and Survival, Cellular Damage and Defense, Clinical Research, and Cancer Prevention and Control. Support is also requested for 9 shared resources: Bioanalytical Laboratory, Biostatistics, Cell and Viral Vector Core Laboratory, Cellular Imaging, Clinical Research Management, Crystallography and Computational Biosciences, Flow Cytometry, Microarray, and Tumor Tissue. For the next funding cycle, we have carefully crafted a strategic plan to reduce the burden of cancer in our region and in the nation.

Public Health Relevance

The Center serves a geographically contiguous, primarily rural area that spans seven states. In this region, the CCCWFU is the primary tertiary center for cancer care. The region has complex racial and ethnic populations that have traditionally not had access to state-of-the-art cancer prevention and treatment. The CCCWFU will not only continue to develop new areas of cancer treatment and prevention, but assure that our region has access to these advances.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA012197-39S2
Application #
8790586
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-02-01
Project End
2017-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
39
Fiscal Year
2014
Total Cost
$67,420
Indirect Cost
$23,522
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Mirlohi, Susan; Duncan, Susan E; Harmon, Michele et al. (2015) Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors. Clin Oral Investig 19:127-37
Gmeiner, William H; Jennings-Gee, Jamie; Stuart, Christopher H et al. (2015) Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway. Leuk Res 39:229-35
Sohl, Stephanie J; Levine, Beverly; Avis, Nancy E (2015) Evaluation of the Quality of Life in Adult Cancer Survivors (QLACS) scale for early post-treatment breast cancer survivors. Qual Life Res 24:205-12
Gmeiner, William H; Boyacioglu, Olcay; Stuart, Christopher H et al. (2015) The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2. Prostate 75:360-9
Randle, Reese W; Doud, Andrea N; Levine, Edward A et al. (2015) Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 22:1634-8
Doud, Andrea N; Randle, Reese W; Clark, Clancy J et al. (2015) Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 22:1645-50
Yosipovitch, Gil; Mills, Kyle C; Nattkemper, Leigh A et al. (2014) Association of pain and itch with depth of invasion and inflammatory cell constitution in skin cancer: results of a large clinicopathologic study. JAMA Dermatol 150:1160-6
Milliron, Brandy-Joe; Vitolins, Mara Z; Tooze, Janet A (2014) Usual dietary intake among female breast cancer survivors is not significantly different from women with no cancer history: results of the National Health and Nutrition Examination Survey, 2003-2006. J Acad Nutr Diet 114:932-7
Jordan, Jennifer H; D'Agostino Jr, Ralph B; Hamilton, Craig A et al. (2014) Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonan Circ Cardiovasc Imaging 7:872-9
Vatca, M; Lucas Jr, J T; Laudadio, J et al. (2014) Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy. Oral Oncol 50:869-76

Showing the most recent 10 out of 161 publications